Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 08:29, 8 November 2010 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: InChI1 InChIKey1 SMILES UNII.← Previous edit		Latest revision as of 07:08, 30 September 2024 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,153 edits rank
(258 intermediate revisions by more than 100 users not shown)
Line 1:		Line 1:
			{{Short description|Chemical compound}}
	{{drugbox
			{{Redirect2|Bonine|Dramamine II|the surname|Bonine (surname)||Dramamine (disambiguation)}}
			{{Use dmy dates|date=October 2022}}
			{{cs1 config |name-list-style=vanc |display-authors=6}}
			{{Infobox drug
			| Verifiedfields = changed
	| Watchedfields = changed		| Watchedfields = changed
	| verifiedrevid = 304592550		| verifiedrevid = 402382239
	| IUPAC_name = (''R/S'')-1--4-(3-methylbenzyl)piperazine
	| image = Meclizine.svg		| image = Meclizine.svg
	| width = 200px		| width = 200
			| alt =
	| CASNo_Ref = {{cascite|correct|CAS}}
	| UNII = 3L5TQ84570
			<!-- Clinical data -->
	| InChI1 = 1/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
			| pronounce =
	| InChIKey1 = OCJYIGYOJCODJL-UHFFFAOYAY
			| tradename = Bonine, Antivert, others
			| Drugs.com = {{drugs.com|monograph|meclizine-hydrochloride}}
			| MedlinePlus = a682548
			| DailyMedID = Meclizine
			| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
			| pregnancy_AU_comment =
			| pregnancy_category =
			| routes_of_administration = ], ], ]
			| class =
			| ATC_prefix = R06
			| ATC_suffix = AE05
			| ATC_supplemental =
			<!-- Legal status -->
			| legal_AU = S4
			| legal_AU_comment =
			| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
			| legal_BR_comment =
			| legal_CA = OTC
			| legal_CA_comment =
			| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
			| legal_DE_comment =
			| legal_NZ = <!-- Class A, B, C -->
			| legal_NZ_comment =
			| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
			| legal_UK_comment =
			| legal_US = OTC
			| legal_US_comment =
			| legal_EU =
			| legal_EU_comment =
			| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
			| legal_UN_comment =
			| legal_status = <!-- For countries not listed above -->
			<!-- Pharmacokinetic data -->
			| bioavailability = 22 - 32%<ref name="bioavail">{{cite journal | vauthors = Sun J, Liu J, Zhang J, Xia H |title=Meclizine-loaded nanostructured lipid carriers to manage nausea and vomiting: Oral bioavailability improvement |journal=Journal of Drug Delivery Science and Technology |date=June 2021 |volume=63 |pages=102432 |doi=10.1016/j.jddst.2021.102432}}</ref>
			| protein_bound =
			| metabolism = ] (])
			| metabolites =
			| elimination_half-life = 5-6 hours<ref name="pharmacokinetics">{{cite journal | vauthors = Wang Z, Lee B, Pearce D, Qian S, Wang Y, Zhang Q, Chow MS | title = Meclizine metabolism and pharmacokinetics: formulation on its absorption | journal = Journal of Clinical Pharmacology | volume = 52 | issue = 9 | pages = 1343–1349 | date = September 2012 | pmid = 21903894 | doi = 10.1177/0091270011414575 }}</ref>
			| duration_of_action =
			| excretion =
			<!-- Identifiers -->
			| CAS_number_Ref = {{cascite|correct|??}}
	| CAS_number = 569-65-3		| CAS_number = 569-65-3
	| ChemSpiderID = 3894
	| ATC_prefix = A04
	| ATC_suffix = AB04
	| ATC_supplemental = {{ATC|R06|AE05}}
	| PubChem = 4034		| PubChem = 4034
			| IUPHAR_ligand = 2757
	| DrugBank = APRD00354
			| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
	| smiles = Clc1ccc(cc1)C(c2ccccc2)N3CCN(CC3)Cc4cccc(c4)C
			| DrugBank = DB00737
			| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
			| ChemSpiderID = 3894
			| UNII_Ref = {{fdacite|correct|FDA}}
			| UNII = 3L5TQ84570
			| KEGG = D08163
			| KEGG2 = D01317
			| ChEBI =
			| ChEMBL_Ref = {{ebicite|changed|EBI}}
			| ChEMBL = 1623
			| NIAID_ChemDB =
			| PDB_ligand =
			| synonyms = Meclozine
			<!-- Chemical and physical data -->
			| IUPAC_name = (''RS'')-1--4-(3-methylbenzyl)piperazine
	| C=25 | H=27 | Cl=1 | N=2		| C=25 | H=27 | Cl=1 | N=2
			| SMILES = Clc1ccc(cc1)C(c2ccccc2)N3CCN(CC3)Cc4cccc(c4)C
	| molecular_weight = 390.948 g/mol
			| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
			| StdInChI = 1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
			| StdInChI_comment =
			| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
			| StdInChIKey = OCJYIGYOJCODJL-UHFFFAOYSA-N
			| density =
			| density_notes =
			| melting_point =
			| melting_high =
			| melting_notes =
	| boiling_point = 230		| boiling_point = 230
	| bioavailability =		| boiling_notes =
	| protein_bound =		| solubility =
			| sol_units =
	| metabolism = hepatic
			| specific_rotation =
	| elimination_half-life = 6 hours
	| pregnancy_US= B
	| legal_status = ] (]); ] (])
	| routes_of_administration = Oral, Sublingual/Buccal
	}}		}}
	'''Meclizine''' is an ] considered to be an ]. It is sold under the brand names of '''Bonine''', '''Bonamine''', '''Antivert''', '''Postafen''', '''Sea Legs''', and '''Dramamine (Less Drowsy Formulation)'''. '''Emesafene''' is a combination of meclizine (1/3) and ] (2/3). In Canada, Antivert Tab (which is no longer available) was a combination of meclizine and ].<ref>DrugBank. David Wishard: University of Alberta, Canada. Accessed November 7, 2010.</ref>
			<!-- Definition and medical uses -->
			'''Meclizine''', sold under the brand name '''Bonine''', among others, is an ] used to treat ] and dizziness (]).<ref name=AHFS2019>{{cite web |title=Meclizine Hydrochloride Monograph for Professionals |url=https://www.drugs.com/monograph/meclizine-hydrochloride.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=22 March 2019 }}</ref> It is taken by mouth.<ref name=AHFS2019/> Effects generally begin in an hour and last for up to a day.<ref name=AHFS2019/>
			<!-- Side effects and mechanisms -->
	==Classification==
			Common side effects include sleepiness and dry mouth.<ref name=AHFS2019/> Serious side effects may include ].<ref name=AHFS2019/> Use in ] appears safe, but has not been well studied; use in ] is of unclear safety.<ref name=Preg2019>{{cite web |title=Meclizine Use During Pregnancy |url=https://www.drugs.com/pregnancy/meclizine.html |website=Drugs.com |access-date=3 March 2019}}</ref> It is believed to work in part by ] and ] mechanisms.<ref name=AHFS2019/>
	Meclizine is a first-generation antihistamine of the ] class. Meclizine is structurally and pharmacologically similar to buclizine, cyclizine, and hydroxyzine. It is used as an antivertigo/antiemetic agent, specifically, in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. <ref>Clinical Pharmacology. , revised November 20, 2009, accessed November 7, 2010.</ref>
			<!-- Society and culture -->
	==Mechanism of Action==
			Meclizine was patented in 1951 and came into medical use in 1953.<ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=547 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA547 }}</ref> It is available as a ] and often ].<ref name=AHFS2019/><ref>{{cite book | vauthors = Cappa M, Cianfarani S, Ghizzoni L, Loche S, Maghnie M |title=Advanced Therapies in Pediatric Endocrinology and Diabetology: Workshop, Rome, October 2014 |date=2015 |publisher=Karger Medical and Scientific Publishers |isbn=9783318056372 |page=101 |url=https://books.google.com/books?id=myNRCwAAQBAJ&pg=PA101 }}</ref> In 2022, it was the 129th most commonly prescribed medication in the United States, with more than 4{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Meclizine Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Meclizine | access-date = 30 August 2024 }}</ref>
	Meclizine is an antagonist at H1-receptors. It possesses ], central nervous system depressant, and local anesthetic effects. Its ] and antivertigo effects are not fully understood, but its central ] properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary ]. <ref>Clinical Pharmacology. , revised November 20, 2009, accessed November 7, 2010.</ref>
	==Uses==		==Medical uses==
			Meclizine is used to treat symptoms of ].<ref name="Houston_2022">{{cite book | vauthors = Houston BT, Chowdhury YS | chapter = Meclizine | date = 18 July 2022 | title = StatPearls | location = Treasure Island (FL) | publisher = StatPearls Publishing | pmid = 32809480 | doi = | chapter-url = https://pubmed.ncbi.nlm.nih.gov/32809480/ }}</ref>
	Meclizine is FDA approved to treat symptoms of ] and for management of ] that stems from diseases affecting the ]. Meclizine's saftey and efficacy in children younger than 12 years old has not been established, therefore use in this population is not recommended. Also, meclizine should be taken with caution in the elderly (greater than 65 years old) because of increased risk of confusion and amnesia. <ref>MICROMEDEX 2.0. . Accessed November 7, 2010.</ref>
	===Motion sickness===		===Motion sickness===
	Meclizine is effective in inhibiting the symptoms of ], such as nausea, vomiting, and dizziness. The recommended dose is 25-50 mg orally, taken 1 hour before travel. The dose may be repeated every 24 hours as needed.<ref>Clinical Pharmacology. , revised November 20, 2009, accessed November 7, 2010.</ref>		Meclizine is effective in inhibiting nausea, vomiting, and dizziness caused by ].<ref>{{Cite web|url=https://www.webmd.com/drugs/2/drug-144800/motion-sickness-meclizine-oral/details|title=Drugs & Medications|website=www.webmd.com|access-date=28 December 2018}}</ref>
			The drug is safe for treating ] and is a first-line therapy for this use.<ref>{{cite journal|url=http://www.arznei-telegramm.de/html/2009_10/0910087_01.html|journal=Arznei-Telegramm|title=Antiemetische Therapie bei Schwangerschaftserbrechen|trans-title=Antiemetic therapy in pregnancy|year=2009|volume=40|pages=87–89|language=de}}</ref><ref>{{cite web | url = http://www.embryotox.de/meclozin.html | work = Embryotox | title = Meclozin | language = de | publisher = Bundesministerium für Gesundheit | trans-title = Federal Ministry of Health }}</ref> Meclizine may not be strong enough for especially sickening motion stimuli, and second-line defenses should be tried in those cases.<ref>{{cite web | vauthors = Lawson BD, McGee HA, Castaneda MA, Golding JF, Kass SJ, McGrath CM | title = Evaluation of several common antimotion sickness medications and recommendations concerning their potential usefulness during special operations. | publisher = Naval Aerospace Research Lab | location = Pensacola, Florida | date = 2 December 2009 | url = http://oai.dtic.mil/oai/oai?verb=getRecord&metadataPrefix=html&identifier=ADA511823 | access-date = 7 February 2016 | archive-url = https://web.archive.org/web/20160427090307/http://oai.dtic.mil/oai/oai?verb=getRecord&metadataPrefix=html&identifier=ADA511823 | archive-date = 27 April 2016 | url-status = dead }}</ref>
	===Vertigo===		===Vertigo===
			Meclizine may be used to treat ], such as in those with ].<ref>{{cite journal | vauthors = Nakashima T, Pyykkö I, Arroll MA, Casselbrant ML, Foster CA, Manzoor NF, Megerian CA, Naganawa S, Young YH | title = Meniere's disease | journal = Nature Reviews. Disease Primers | volume = 2 | pages = 16028 | date = May 2016 | pmid = 27170253 | doi = 10.1038/nrdp.2016.28 | s2cid = 3987838 }}</ref><ref>{{cite book | vauthors = | chapter = Meclizine | title = LiverTox: Clinical and Research Information on Drug-Induced Liver Injury | date = January 2017 | pmid = 31643231 | chapter-url = https://www.ncbi.nlm.nih.gov/books/NBK547895/ | location = Bethesda (MD) | publisher = National Institute of Diabetes and Digestive and Kidney Diseases }}</ref>
	Meclizine may be effective in relieving ] experienced as a result of ]s or other conditions. The recommended dose is 25-100 mg per day orally, separated into divided doses. <ref>Clinical Pharmacology. , revised November 20, 2009, accessed November 7, 2010.</ref>
			==Side effects==
			Some common side effects such as drowsiness, dry mouth, and tiredness may occur. Meclizine has been shown to have fewer dry mouth side effects than the traditional treatment for motion sickness, transdermal ].<ref name="pmid6734040">{{cite journal | vauthors = Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L | title = Transdermal scopolamine, oral meclizine, and placebo in motion sickness | journal = Clinical Pharmacology and Therapeutics | volume = 36 | issue = 1 | pages = 116–120 | date = July 1984 | pmid = 6734040 | doi = 10.1038/clpt.1984.148 | s2cid = 40691502 }}</ref> A very serious allergic reaction to this drug is unlikely, but immediate medical attention should be sought if it occurs. Symptoms of a serious allergic reaction may include rash, itching, swelling, severe dizziness, and trouble breathing.<ref>{{cite web | url = http://www.medicinenet.com/meclizine_cyclizine-oral/article.htm | title = Meclizine - oral, Antivert, D-vert, Dramamine II | access-date = 7 November 2010 | work = MedicineNet }}</ref>
	==Side Effects==		== Pharmacology ==
			=== Pharmacodynamics ===
	Some common side effects such as drowsiness, dry mouth, and tiredness may occur. Meclizine has been shown to have less dry mouth side effects than the traditional treatment for motion sickness, transdermal ]<ref>Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L. Clinical Pharmacology And Therapeutics 1984 Jul; Vol. 36 (1), pp. 116-20. Available from: MEDLINE: Ipswich, MA. PMID 6734040</ref>. A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling, severe dizziness, and/or trouble breathing. <ref> MedicineNet.com: We Bring Doctors' Knowledge to You. MedicineNet Inc, San Clemente, CA. . Accessed November 7, 2010.</ref>
			Meclizine is an antagonist at H<sub>1</sub> receptors (''K''<sub>i</sub> = 250 nM).<ref>{{cite journal | vauthors = Tran VT, Chang RS, Snyder SH | title = Histamine H1 receptors identified in mammalian brain membranes with mepyramine | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 75 | issue = 12 | pages = 6290–6294 | date = December 1978 | pmid = 282646 | pmc = 393167 | doi = 10.1073/pnas.75.12.6290 | doi-access = free }}</ref> It possesses ], ], and ] effects. Its ] and antivertigo effects are not fully understood, but its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and ] stimulation, and it may affect the medullary ].<ref name="Houston_2022" /> The drug has been shown to reduce the magnitude of the ] in healthy volunteers.<ref name="weerts">{{cite journal | vauthors = Weerts AP, De Meyer G, Pauwels G, Vanspauwen R, Dornhoffer JL, Van de Heyning PH, Wuyts FL | title = Pharmaceutical countermeasures have opposite effects on the utricles and semicircular canals in man | journal = Audiology & Neuro-Otology | volume = 17 | issue = 4 | pages = 235–242 | date = 2012 | pmid = 22517315 | doi = 10.1159/000337273 }}</ref> At the same time the drug was found to have only a small (and statistically insignificant) effect on the motion sensitivity of the ].<ref name="weerts"/> Much as motion sickness arises from a discrepancy between multiple senses, meclizine most likely affects a wide array of sensory mechanisms related to self-motion while leaving the core vestibular response intact.<ref>{{cite journal | vauthors = Wibble T, Engström J, Verrecchia L, Pansell T | title = The effects of meclizine on motion sickness revisited | journal = British Journal of Clinical Pharmacology | volume = 86 | issue = 8 | pages = 1510–1518 | date = August 2020 | pmid = 32077140 | pmc = 7373708 | doi = 10.1111/bcp.14257 | doi-access = free }}</ref>
			Meclizine also has been reported to be a weak ] at D<sub>1</sub>-like and D<sub>2</sub>-like receptors{{citation needed|date=September 2015}} but it does not cause ] in mice, perhaps because of its anticholinergic activity.<ref name=Haraguchi_1997>{{cite journal | vauthors = Haraguchi K, Ito K, Kotaki H, Sawada Y, Iga T | title = Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies | journal = Drug Metabolism and Disposition | volume = 25 | issue = 6 | pages = 675–684 | date = June 1997 | pmid = 9193868 | url = http://dmd.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9193868 | access-date = 12 June 2014 | url-status = dead | archive-url = https://web.archive.org/web/20210828114146/https://dmd.aspetjournals.org/content/25/6/675.long | archive-date = 28 August 2021 }} "Catalepsy was assessed by the bar method: the front paws were gently placed on a horizontal metal bar with 2 mm diameter suspended 4 cm above, and the length of time the mouse maintains this abnormal posture was measured." </ref> The drug does not effect dopamine or serotonin reuptake.<ref>{{cite journal | vauthors = Oishi R, Shishido S, Yamori M, Saeki K | title = Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 349 | issue = 2 | pages = 140–144 | date = February 1994 | pmid = 7513381 | doi = 10.1007/BF00169830 }}</ref>
	===Drowsiness===
	Drowsiness may result as a side effect of taking meclizine. Users are advised not to operate heavy machinery while under the influence. The consumption of alcohol while under the influence of meclizine may result in additional drowsiness.
			=== Pharmacokinetics ===
	===Special Considerations in the Elderly===
			Meclizine reaches peak plasma concentration in about 1.5 hours and has an elimination half-life of 5-6 hours.<ref name="pharmacokinetics"/> Despite its relatively short half-life, the drug is reported to remain effective for motion sickness for 12 - 24 hours.<ref>{{cite web |title=ANTIVERT FDA Drug Facts |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/010721s058lbl.pdf |publisher=FDA |access-date=18 June 2024}}</ref> Meclizine has low bioavailability (22–32%) and a delayed onset to action in part due to its poor solubility in water (0.1 mg/ml) and gastrointestinal fluid.<ref name="bioavail"/> In children it has been found that taking meclizine with food increases its bioavailability slightly.<ref name="kids">{{cite journal | vauthors = Kitoh H, Matsushita M, Mishima K, Nagata T, Kamiya Y, Ueda K, Kuwatsuka Y, Morikawa H, Nakai Y, Ishiguro N | title = Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia | journal = PLOS ONE | volume = 15 | issue = 4 | pages = e0229639 | date = 13 April 2020 | pmid = 32282831 | pmc = 7153885 | doi = 10.1371/journal.pone.0229639 | doi-access = free | bibcode = 2020PLoSO..1529639K }}</ref> It is metabolized in the liver by the ] enzyme.<ref name="pharmacokinetics"/> Ten metabolites have been identified.<ref>{{cite journal | vauthors = Goenechea VS, Rücker G, Brzezinka H, Hoffmann G, Neugebauer M, Glanzmann G | title = | journal = Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie und Klinische Biochemie | volume = 26 | issue = 2 | pages = 105–115 | date = February 1988 | pmid = 3367105 }}</ref> In rats, the main metabolite is norchlorcyclizine, which distributes extensively through body tissue.<ref>{{cite journal | vauthors = Narrod SA, Wilk AL, King CT | title = Metabolism of Meclizine in the Rat | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 147 | pages = 380–384 | date = March 1965 | pmid = 14269614 }}</ref>
	As with any ] agent, meclizine may cause '''confusion''' or aggravate symptoms in those with ] in the ] population (those greater than 65 years of age). Therefore '''caution''' should be used when administering meclizine to the elderly. <ref>Merck Manuals, Online Medical Library: Meclizine (Drug Information Provided by Lexi-Comp). , revised January 2010, accessed November 7, 2010.</ref>
	==References==		==Chemistry==
			Meclizine is a ] (nonselective ]) of the ] class. It is structurally and pharmacologically similar to ], ], and ].
	{{reflist}}
	==External links==		===Synthesis===
			(4-Chlorophenyl)-phenylmethanol is halogenated with ] before adding acetylpiperazine. The acetyl group is cleaved with diluted ]. An N-alkylation of the piperazine ring with 3-methylbenzylchloride completes the synthesis.<ref>{{cite book| vauthors = Fuhrkop JH, Li G | title = Organic Synthesis. Concepts and Methods |publisher=Wiley |year=2003 |page=237 |isbn=978-3-527-30272-7 }}</ref>
	*
	*
			]
	*
			Alternatively, the last step can be replaced by a reductive N-alkylation with 3-methylbenzaldehyde. The reductive agent is ], and ] is used as a ].<ref>{{cite patent | country = US | number = 2709169 | inventor = Morren H | assign1 = Union Chimique Belge Société Anonyme | gdate = 24 May 1955 | url = https://patents.google.com/patent/US2709169?oq=US2709169 }}</ref><ref name="Kleemann">{{cite book| vauthors = Kleemann A, Engel J, Kutscher B, Reichert D |title= Pharmaceutical Substances. Synthesis, Patents, Applications |edition=4th |publisher=Thieme |year=2001 |isbn=3-13-115134-X }}</ref>
			]
			Meclizine is obtained and used as a ], a 1:1 mixture of the two ]s. Drug forms contain the racemic dihydrochloride.{{fact|date=August 2020}}
			== Society and culture ==
			=== Brand names ===
			Meclizine is an ].<ref>{{cite web | url = http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf | title = Guidelines on the Use of INNs for Pharmaceutical Substances | date = 1997 | access-date = 1 November 2013 | work = WHO }}</ref>
			It is sold under the brand names Bonine, Bonamine, Antivert, Postafen, Sea Legs, and Dramamine II (Less Drowsy Formulation). Emesafene is a combination of meclizine (1/3) and ] (2/3). In Canada, Antivert Tab was a combination of meclizine and ].<ref>{{cite web | work = DrugBank | url = http://www.drugbank.ca/drugs/DB00737 | title = Drug card for Meclizine | vauthors = Wishard D | publisher = University of Alberta | location = Canada | access-date = 7 November 2010 }}</ref>
			== References ==
			{{reflist}}
			{{Navboxes
			| title = ]
			| titlestyle = background:#ccccff
			| list1 =
	{{Antiemetics}}		{{Antiemetics}}
	{{Cholinergics}}		{{Antihistamines}}
	{{Histaminergics}}		{{Motion sickness}}
	{{Piperazines}}		{{Hallucinogens}}
			}}
			{{Navboxes
			| title = ]
			| titlestyle = background:#ccccff
			| list1 =
			{{Histamine receptor modulators}}
			{{Ion channel modulators}}
			{{Muscarinic acetylcholine receptor modulators}}
			{{Xenobiotic-sensing receptor modulators}}
			}}
			{{Portal bar | Medicine}}
			{{Authority control}}
	]		]
	]		]
	]		]
			]
			]
	]
			]
	]
			]
	]
	]
	]
	]